11 – 20 of 25
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2011
-
Mark
SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus
(
- Contribution to journal › Article
-
Mark
Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity
(
- Contribution to journal › Article
-
Mark
Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus
(
- Contribution to journal › Article
- 2010
-
Mark
Atherosclerotic Vascular Events in a Multinational Inception Cohort of Systemic Lupus Erythematosus
(
- Contribution to journal › Article
-
Mark
Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus
(
- Contribution to journal › Article
- 2009
-
Mark
Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas:relative risks and time-trends in the Swedish Biologics Register
(
- Contribution to journal › Article
-
Mark
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
(
- Contribution to journal › Article
-
Mark
EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints
(
- Contribution to journal › Scientific review
-
Mark
EULAR points to consider for conducting clinical trials in systemic lupus erythematosus
(
- Contribution to journal › Article
- 2008
-
Mark
EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics
(
- Contribution to journal › Scientific review